Epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in cervical cancer cells.docVIP

 PAGE \* MERGEFORMAT 5 Epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in cervical cancer cells [Abstract] Objective To investigate the selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in cervical cancer cells. Methods Siha cervical squamous cell carcinoma cells, adenocarcinoma Hela cells were studied using the MTT assay the use of ZD1839 monotherapy as well as with cisplatin, respectively Siha and Hela cell proliferation. Analysis using Burgi the effect of combination therapy, and use flow cytometry Siha and Hela cells, cell cycle distribution and apoptosis rate of change. The results alone ZD1839 can inhibit Siha, Hela cell proliferation, their IC50 values were 1.48μ mol / L, 2.67μ mol / L, and the inhibition in a dose-dependent. ZD1839 enhances cisplatin Siha, Hela cells in vitro, Burgi correction formula derived from Q values were 1.06 ± 0.03 (Siha), 1.13 ± 0.01 (Hela). ZD1839 to G0/G1 phase cells increased, S phase cells decreased apoptosis rate increased. Conclusion ZD1839 can inhibit cancer cell proliferation and can enhance cisplatin in cervical cancer cells in vitro, the inhibition of tumor cells may be related to a standstill in the G1 phase and inducing tumor cell apoptosis. [Keywords:] cervical cancer; ZD1839; cell proliferation; cell cycle; apoptosis The incidence of cervical cancer accounted for the top female genital malignancies. Currently, radiotherapy is the main treatment, but the effects are not satisfactory. To further enhance its efficacy, it is research, including cisplatin and other chemotherapeutic drugs, including a comprehensive treatment, despite a certain degree of efficacy, but serious toxic side effects limit its application. ZD1839 is a new development for the selective oral epidermal growth factor receptor tyrosine kinase inhibitor, has been U.S. FDA approved for advanced non-small cell lung cancer treatment. As the existence of cervical cancer cells of high epidermal growth fact